The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19.

ABSTRACT:

Objectives

This study aimed to estimate the cost-effectiveness of remdesivir, the first novel therapeutic to receive Emergency Use Authorization for the treatment of hospitalized patients with COVID-19, and identify key drivers of value to guide future pricing and reimbursement efforts.

Methods

A Markov model evaluated the cost-effectiveness of remdesivir in patients hospitalized with COVID-19 from a US healthcare sector perspective. A lifetime time horizon captured potential long-term costs and outcomes. Model outcomes included discounted total costs, life-years, and quality-adjusted life-years (QALYs). Remdesivir was modeled as an addition to standard of care and compared with standard of care alone, including dexamethasone for patients requiring respiratory support. COVID

SUBMITTER: Whittington MD 

PROVIDER: S-EPMC8856900 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature